---------- Forwarded message ---------- From: Ronald Raphael <[EMAIL PROTECTED]> Date: Jul 9, 2007 12:57 PM Subject: [Imc-rm-announce] Check out this short news clip on MGRM To: [EMAIL PROTECTED], [EMAIL PROTECTED], [EMAIL PROTECTED], [EMAIL PROTECTED], [EMAIL PROTECTED], [EMAIL PROTECTED], [EMAIL PROTECTED]
Friends, wow great video from the very much respected San Francisco Bay Area T.V. station on MGRM and did you see how clean the MGRM Laboratory was? looks like a well run Company no wonder Pfizer, Mreck, Shering and European Pharama Companies Respect and Rely on MGRM HIV Troflie testing and I can see why the FDA respected the highly professional staff at MGRM and the data from MGRM and Pfizer during Clincal trials on Maraviroc/Celsentri HIV drug and with such accurate and trustworthy data the FDA was able to recommend unanimously 12-0 for fast track approval for Maraviroc/Celsentri. I suspect we shall all see soon the labeling issue on Pfizer & FDA concluded anyday now maybe even today and Maraviroc/Celsentri HIV drug along with MGRM Trofile test will then be Marketed World Wide by Pfizer as planned. Thanks nettripper2002 for posting this fantastic link. Broadcast states the price for the trofile test is $1500. 40,000 possible candidates for Maraviroc in the US alone gives us enough revenue for an easy double. (40000 x 1500 = 60,000,000 in revenues.) And if PFE can get the FDA to broaden the Maraviroc label the uptake could be much larger. I really liked the last line of the report "It sounds like it's expensive but I guess if it saves your life it's well worth it. Not only that Insurance companies will pay for it because they found that by avoiding even one month of very expensive medication it's well worth the $1500 cost." Check out this short news clip on MGRM - http://www.ktvu.com/video/9295652/index.... I stumbled across this video this early a.m. and was fascinated by it and wanted to share it with the rest of you MGRM'ers. I may not be as astute as you in detail, however, I intuitively caught the enthusiasm radiating on William Young's face when he spoke. i.e. (non-verbal communication.) As you are well aware of companies cannot disclose every aspect of their doings. Young gave his vote of confidence in that clip. SOUTH SAN FRANCISCO, Calif., June 25 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM - News) announced today that William D. Young, CEO and Chairman, is scheduled to present a corporate overview at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July 11, 2007 at 3:00 p.m. (Eastern Time) at the Mandarin Oriental Hotel in New York City, New York. To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page. About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com. PFE Monogram's collaborator, Pfizer Inc meeting is on the 18th ..said it has received an approvable letter from the FDA for maraviroc, a CCR5-antagonist under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. The Trofile assay was used to select the more than 2,000 patients worldwide who have received treatment with maraviroc through clinical trials, the South San Francisco, Calif.-based biotechnology company said. Trofile is currently in use for patient selection in Pfizer's ongoing expanded access program, the company noted. One trend called "personalized medicine" will change medicine. Major drug companies are using personalized tests to develop new and better medicine - medicine that will target diseases that are specific to individual patients. It's only a matter of time before the entire medical world is catering to your specific ailments. This tiny company's patented testing solutions enable doctors to tailor their treatments to the precise needs of each patient. In fact, this "next generation" of medical tests has proven to be close to 100% accurate. The best any of Daily's mentioned less-advanced mainstream tests could get was a 65% accuracy rate. That's why this $220 million company will soon emerge as a leader in personalized medicine. And it's also why doctors around the world will trust this company's tests to help them treat their patients. With the technology to make personalized medicine mainstream, this company will not be trading at $1.68 a share for too much longer. Right now, some of the biggest and most cutting-edge drug companies in the world are using sophisticated new tests. These tests help to better select patients for clinical trials for new HIV and cancer treatments. And soon, physicians across the globe will be using these same techniques to treat patients will all sorts of diseases. Not just HIV. The developer of these diagnostic tests isn't Merck or Pfizer. Instead, it's a small $220 million firm. This one small company has partnered with more than 60 pharmaceutical, biotech and research organizations. This includes almost every company with a significant HIV drug development program. The bottom line is that any company that wants to gain a foothold in HIV treatments needs this unknown company to survive. This drug company savior is Monogram Biosciences, Inc. MGRM: NASDAQ). The company develops special testing products that are so accurate that the big pharmaceutical companies are using the technology to develop better treatments. It's all part of the new personalized medicine trend. As technology improves, it is becoming possible for doctors and drug companies to diagnose exactly what strain of the disease patients have. From there, physicians can better treat their patients using very specific drugs. But it's not just a simple HIV test that makes Monogram such an important company. Twenty years ago, all HIV-positive patients were treated the same and had short life expectancies. But now, treatments are getting far more advanced. We're seeing those who suffer from the virus living longer lives. Unfortunately, with more advanced treatments comes a disease that has begun to mutate and become even more deadly. You see, different strains and mutations of HIV exist. That's what makes viruses so deadly. They can adapt to work around the current treatments that are widely used today. This is why Monogram's tests are important. This company's unique tests tell physicians and drug companies what specific viruses a patient has in his body and how the viruses are spreading through his system. Once they have this information, doctors can prescribe specific drugs that help target the specific virus strains and block how the disease infects healthy cells. As these specialty drugs are developed, doctors across the globe will rely on these tests to tell them if the drugs will work for their patients. Including those with the most deadly diseases known to man. _______________________________________________ Imc-colorado-announce mailing list [EMAIL PROTECTED] http://lists.indymedia.org/mailman/listinfo/imc-colorado-announce
